Article | March 23, 2016

Streamlining Recombinant Protein Production

Source: Ajinomoto Althea, Inc.
Ajinomoto Althea, Inc.

The pharmaceutical industry is undergoing a deep transformation from small molecule drugs to biologics. Over the last decade, the percentage share of biologic-based drugs -- including vaccines, therapeutic proteins and monoclonal antibodies -- has seen a steady growth of 13.3 percent per year, compared to a 4.2 percent decrease for other drugs.  Biologics now account for 55 percent of new drug approvals and 64 percent of pipeline drugs.1 By 2016, biologics are projected to account for approximately 17 percent of total global spending on medicines, reaching an overall market value of up to $210 billion.2 Use of recombinant proteins as therapeutics has become an attractive strategy for altering the biology of disease progression and offers significant commercial opportunities.